相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
David A. Griffith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers
Clinical Diabetes (2021)
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2021)
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen et al.
EXPERT OPINION ON EMERGING DRUGS (2021)
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena et al.
NATURE MEDICINE (2021)
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Dhiren Patel et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
D. J. Brayden et al.
ADVANCED DRUG DELIVERY REVIEWS (2020)
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Takahiro Kawai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Nanoparticles: Oral Delivery for Protein and Peptide Drugs
Shu-jun Cao et al.
AAPS PHARMSCITECH (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Charlotte Granhall et al.
CLINICAL PHARMACOKINETICS (2019)
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera et al.
DIABETES THERAPY (2019)
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones et al.
NATURE COMMUNICATIONS (2018)
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
Feng Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
P. Barrington et al.
DIABETES OBESITY & METABOLISM (2011)
G protein-coupled receptor sorting to endosomes and lysosomes
Adriano Marchese et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)